首页> 外文OA文献 >Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

【2h】

Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

机译：获得含有激活EGFR突变的MET扩增的EGFR-TKI肺腺癌中的抗性机制以组合Met-TKI / EGFR-TKI暴露的抗性机制

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Toshimitsu Yamaoka; Tohru Ohmori; Motoi Ohba; Satoru Arata; Yasunari Kishino; Yasunori Murata; Sojiro Kusumoto; Hiroo Ishida; Takao Shirai; Takashi Hirose; Tsukasa Ohnishi; Yasutsuna Sasaki;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation [J] . Yamaoka Toshimitsu, Ohmori Tohru, Ohba Motoi, Molecular cancer therapeutics . 2016,第12期

机译：Met-TKI / EGFR-TKI联合暴露在Met扩增的EGFR-TKI耐药肺腺癌中具有激活的EGFR突变的获得性耐药机制
2. Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI [J] . Yusuke Okuma, Yukio Hosomi Journal of Thoracic Disease . 2017,第3期

机译：Osimertinib用于高级非小细胞肺癌，涉及EGFR突变外显子20 T790M，获得第一或第二代EGFR-TKI的抗性突变
3. EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice [J] . Higo Hisao, Ohashi Kadoaki, Makimoto Go, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2019,第期

机译：EGFR-TKI在免疫活性剂C57BL / 6J小鼠中携带EGFR突变的肺癌抗性
4. EGFR Mutations in Lung Adenocarcinoma: Correlation with F-18 FDG PET/CT [C] . Jinyoung Yoo, Sonya Youngju Park International Molecular Medicine Tri-Conference. . 2016

机译：肺腺癌的EGFR突变：与F-18 FDG PET / CT的相关性
5. The Effectiveness of EGFR-TKIs in Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis. [D] . Li, Xiao. 2016

机译：EGFR-TKIs在非小细胞肺癌治疗中的有效性：一项荟萃分析。
6. Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M acquired resistant mutation for first- or second-generation EGFR-TKI [O] . Yusuke Okuma, Yukio Hosomi 2017

机译：奥西替尼用于携带EGFR突变外显子20 T790M的晚期非小细胞肺癌第一代或第二代EGFR-TKI的获得性耐药突变
7. Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI [O] . Yusuke Okuma, Yukio Hosomi 2017

机译：Osimertinib用于高级非小细胞肺癌，涉及EGFR突变外显子20 T790M，获得第一或第二代EGFR-TKI的抗性突变
8. Deficient BIM Expression as a Mechanism of Intrinsic and Acquired Resistance to Targeted Therapies in EGFR Mutant and ALK Positive Lung Cancers. [R] . Sequist, L., Engelman, J. 2016

机译：缺乏BIm表达作为EGFR突变体和aLK阳性肺癌中靶向治疗的内在和获得性抗性的机制。

Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

著录项

引文网络

相似文献

相关主题

期刊订阅